Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6778 | 1368 | 35.3 | 70% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CD23 | Author keyword | 57 | 38% | 9% | 118 |
2 | SOLUBLE CD23 | Author keyword | 21 | 55% | 2% | 26 |
3 | LOW AFFINITY IGE RECEPTOR | Author keyword | 17 | 100% | 1% | 8 |
4 | FC EPSILON RII | Author keyword | 14 | 59% | 1% | 16 |
5 | CD23 FC EPSILON RII | Author keyword | 8 | 75% | 0% | 6 |
6 | IGE BINDING FACTORS | Author keyword | 6 | 100% | 0% | 4 |
7 | FC EPSILON RII CD23 | Author keyword | 4 | 75% | 0% | 3 |
8 | SCD23 | Author keyword | 4 | 29% | 1% | 12 |
9 | RECH ALLERGIE | Address | 3 | 57% | 0% | 4 |
10 | ANTI CD23 | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CD23 | 57 | 38% | 9% | 118 | Search CD23 | Search CD23 |
2 | SOLUBLE CD23 | 21 | 55% | 2% | 26 | Search SOLUBLE+CD23 | Search SOLUBLE+CD23 |
3 | LOW AFFINITY IGE RECEPTOR | 17 | 100% | 1% | 8 | Search LOW+AFFINITY+IGE+RECEPTOR | Search LOW+AFFINITY+IGE+RECEPTOR |
4 | FC EPSILON RII | 14 | 59% | 1% | 16 | Search FC+EPSILON+RII | Search FC+EPSILON+RII |
5 | CD23 FC EPSILON RII | 8 | 75% | 0% | 6 | Search CD23+FC+EPSILON+RII | Search CD23+FC+EPSILON+RII |
6 | IGE BINDING FACTORS | 6 | 100% | 0% | 4 | Search IGE+BINDING+FACTORS | Search IGE+BINDING+FACTORS |
7 | FC EPSILON RII CD23 | 4 | 75% | 0% | 3 | Search FC+EPSILON+RII+CD23 | Search FC+EPSILON+RII+CD23 |
8 | SCD23 | 4 | 29% | 1% | 12 | Search SCD23 | Search SCD23 |
9 | ANTI CD23 | 2 | 67% | 0% | 2 | Search ANTI+CD23 | Search ANTI+CD23 |
10 | CD23 EXPRESSION | 2 | 67% | 0% | 2 | Search CD23+EXPRESSION | Search CD23+EXPRESSION |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | FC EPSILON RII CD23 | 81 | 75% | 4% | 58 |
2 | LOW AFFINITY RECEPTOR | 81 | 51% | 8% | 114 |
3 | IGE BINDING FACTORS | 80 | 70% | 5% | 67 |
4 | FC EPSILON RII | 65 | 67% | 4% | 58 |
5 | SOLUBLE CD23 | 61 | 47% | 7% | 96 |
6 | HUMAN LYMPHOCYTE RECEPTOR | 44 | 88% | 2% | 21 |
7 | CD23 | 34 | 31% | 7% | 91 |
8 | LYMPHOCYTE RECEPTOR | 24 | 91% | 1% | 10 |
9 | FACTORS SOLUBLE CD23 | 23 | 86% | 1% | 12 |
10 | FC EPSILON RECEPTOR | 23 | 47% | 3% | 36 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
EXPRESSION, STRUCTURE, AND FUNCTION OF THE CD23 ANTIGEN | 1991 | 177 | 199 | 73% |
THE LOW-AFFINITY RECEPTOR FOR IGE | 1992 | 146 | 90 | 78% |
FC-EPSILON-RII/CD23 - THE LOW AFFINITY RECEPTOR FOR IGE | 1990 | 193 | 126 | 81% |
REGULATION AND DEREGULATION OF HUMAN IGE SYNTHESIS | 1990 | 266 | 33 | 61% |
CD23/Fc epsilon RII: molecular multi-tasking | 2010 | 46 | 121 | 62% |
Anti-CD23 | 2005 | 48 | 118 | 75% |
CD23: An overlooked regulator of allergic disease | 2007 | 28 | 48 | 71% |
CD23 AND B-CELL ACTIVATION | 1995 | 52 | 36 | 69% |
HUMAN IGE-BINDING FACTORS | 1989 | 128 | 43 | 86% |
CD23 AND B-CELL ACTIVATION | 1992 | 50 | 12 | 83% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | RECH ALLERGIE | 3 | 57% | 0.3% | 4 |
2 | U274 | 2 | 67% | 0.1% | 2 |
3 | INFECT DIS SECTBOSTON MED | 1 | 100% | 0.1% | 2 |
4 | INSERM U196 26 RUE ULM | 1 | 100% | 0.1% | 2 |
5 | ALLERGIE M4211K | 1 | 50% | 0.1% | 1 |
6 | BIOMED STUDIES EDINBURGH INFECT DIS | 1 | 50% | 0.1% | 1 |
7 | CLIN IMMUNOL IMMUNOBIOL | 1 | 50% | 0.1% | 1 |
8 | IMMUN INFECT EVOLUT BIOL SCI | 1 | 50% | 0.1% | 1 |
9 | MED M6076 | 1 | 50% | 0.1% | 1 |
10 | MOLEC EXPTL MED ALLERGY SECT | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000157838 | HYBROTEC//ASTER YOMENA//ENERGY TRANSFER PROBE |
2 | 0.0000140528 | AUTOANTI IGE//IGG ANTI IGE//ANTI IGE AUTOANTIBODY |
3 | 0.0000140195 | ALLERGEN FRAGMENTS//AMPLIFICATION FREE//H2 GENOTYPE |
4 | 0.0000130171 | CANCER BIOTHERAPY//IST TIPIZZAZ TISSUTALE PROBLEMI DIALISI//INTRACELLULAR IMMUNOFLUORESCENCE |
5 | 0.0000126516 | OMALIZUMAB//ANTI IGE//ANTI IMMUNOGLOBULIN E |
6 | 0.0000120272 | ATOPY PATCH TEST//ENVIRONM DERMATOL ALLERGY GSF//PAEDIAT ALLERGY SERV |
7 | 0.0000103703 | VET ANAT PATHOL B14//ACINAR CELL CULTURE//COMPREHENS CANC UNIV STN |
8 | 0.0000102923 | ACQUIRED IMMUNODEFICIENCY SYNDROME PATIENTS//ANTI VZV ANTIBODIES//CRSSAIPSC |
9 | 0.0000087278 | EOSINOPHIL CHEMOTACTIC FACTOR//BALL 1//STO 2 DERIVED ECF |
10 | 0.0000083725 | JOURNAL OF MOLECULAR AND CELLULAR IMMUNOLOGY//J11D//MED ICRF HUMAN TUMOUR IMMUNOL GRP |